Showing 61 - 80 results of 160 for search '"Ballerup"', query time: 0.21s Refine Results
  1. 61
  2. 62
  3. 63
  4. 64
  5. 65

    Improvements in Survival and Early Retirement Rates – Real-World Evidence on Danish Breast Cancer Patients 2004–2018 by Khan H, Rudolfsen JH, Olsen J, Borgquist S, Poulsen PB

    Published 2023-01-01
    “…Humma Khan,1 Jan Håkon Rudolfsen,2 Jens Olsen,2 Signe Borgquist,3 Peter Bo Poulsen1 1Pfizer Denmark, Ballerup, Denmark; 2Incentive, Holte, Denmark; 3Department of Oncology, Aarhus University Hospital and Aarhus University, Aarhus, DenmarkCorrespondence: Peter Bo Poulsen, Pfizer Denmark, Lautrupvang 8, Ballerup, 2750, Denmark, Tel +45 2920 3211, Email PeterBo.Poulsen@pfizer.comBackground: Historically, Denmark has had poor survival for cancer patients relative to other western countries with comparable health-care systems. …”
    Get full text
    Article
  6. 66
  7. 67
  8. 68
  9. 69

    The Cost-Effectiveness of Anti-IL17 Biologic Therapies for Moderate-to-Severe Plaque Psoriasis Treatment in Italy and Germany: A Sequential Treatment Analysis by Nyholm N, Danø A, Schnack H, Colombo GL

    Published 2023-07-01
    “…Nanna Nyholm,1 Anne Danø,2 Henrik Schnack,2 Giorgio Lorenzo Colombo3 1LEO Pharma AS, Ballerup, Denmark; 2EY, Frederiksberg, Denmark; 3CEFAT Center of Pharmaceuticals Economics and Medical Technologies Evaluation, Department of Drug Sciences, University of Pavia, Pavia, ItalyCorrespondence: Nanna Nyholm, LEO pharma A/S, Industriparken 55, Ballerup, 2750, Denmark, Tel +45 6178 2096, Email OJYDK@leo-pharma.comObjective: The objective of this study was to optimise the cost-effectiveness of different anti-IL17 treatment sequences used in the treatment of moderate-to-severe plaque psoriasis in Italy and Germany over a five-year time horizon.Methods: We adjusted a previously published treatment sequence model for biologic drugs used in psoriasis treatment to an Italian and German setting, respectively. …”
    Get full text
    Article
  10. 70

    Setting priorities in the health care sector – the case of oral anticoagulants in nonvalvular atrial fibrillation in Denmark by Poulsen PB, Johnsen SP, Hansen ML, Brandes A, Husted S, Harboe L, Dybro L

    Published 2017-10-01
    “…Peter Bo Poulsen,1 Søren Paaske Johnsen,2 Morten Lock Hansen,3 Axel Brandes,4 Steen Husted,5,† Louise Harboe,6 Lars Dybro7 1Pfizer Denmark ApS, Ballerup, 2Department of Clinical Epidemiology, Aarhus University Hospital, 3Department of Cardiology, Zealand University Hospital, Roskilde, 4Department of Cardiology, Odense University Hospital, 5Department of Medicine, Regional Hospital West Jutland, Herning, 6Bristol-Myers Squibb Denmark, Virum, 7Pfizer Denmark, Ballerup, Denmark †Steen Husted passed away on December 28, 2016 Aim: Resources devoted to health care are limited, therefore setting priorities is required. …”
    Get full text
    Article
  11. 71

    Market Readiness for Single-Use Cystoscopes According to Urologists and Procurement Managers Worldwide by Rindorf D, Larsen S, Ockert L, Jung H, Dahl C

    Published 2021-05-01
    “…Dinah Rindorf,1 Sara Larsen,1 Lotte Ockert,1 Helene Jung,2 Claus Dahl3 1Ambu a/S, Ballerup, Denmark; 2Department of Urology, Hospital Lillebaelt, Vejle, Denmark; 3Department of Urology, Capio Ramsey Santé, Hellerup, DenmarkCorrespondence: Dinah RindorfAmbu a/S, Baltorpbakken 13, Ballerup, 2750, DenmarkTel +4550737830Email dihr@ambu.comPurpose: Single-use endoscopes have been subjected to increase awareness in recent years, and several new single-use cystoscopes (eg Ambu® aScope 4 Cysto) have entered the market. …”
    Get full text
    Article
  12. 72
  13. 73
  14. 74
  15. 75
  16. 76
  17. 77
  18. 78
  19. 79
  20. 80